论文部分内容阅读
资料来源:EMA发布时间:2013.03.26欧洲药品局正在调查一项独立的大学研究者关于胰高血糖素样肽-1(glucagon-like-peptide-1,GLP-1)的研究结果。这项研究发现以GLP-为1基础的治疗方法会增加患有2型糖尿病的患者发生胰腺炎和胰胆管上皮癌变的风险。基于GLP-1的治疗方法中的活性物质是肠促胰岛素类似物,其作用效果就像肠降血糖素,增加胰腺在
Source: EMA Publish Date: 2013.03.26 The European Medicines Agency is investigating the findings of an independent university researcher on glucagon-like-peptide-1 (GLP-1). This study found that GLP-1-based treatment increases the risk of pancreatitis and pancreaticobiliary carcinogenesis in patients with type 2 diabetes. The active substance in the GLP-1-based treatment is an incretin analogue that acts like an incretin and increases the activity of the pancreas in